We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Total Net Revenue of $66.9 Million for Q2 2024, Up 36% from Q2 2023 Raises Full-Year 2024 Net Revenue Guidance to $260 Million to $270 Million, Representing Year-Over-Year Growth of 34% at the...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will host an Investor Day on Thursday...
Launching into this growth market1 as part of the company’s geographic expansion strategy Evolus Australia established to drive medical education, training, marketing and sales to medical...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sandra Beaver, CFO, will present at the...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its...
Launching in one of the five largest aesthetic toxin injectable markets in Europe1 as part of the company’s geographic expansion strategy Evolus to provide Nuceiva® for direct order and delivery...
| Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.03 | -0.350058343057 | 8.57 | 8.76 | 8.43 | 1597988 | 8.59952439 | CS |
| 4 | 0.25 | 3.01568154403 | 8.29 | 8.76 | 8.05 | 2206024 | 8.42967525 | CS |
| 12 | -0.24 | -2.73348519362 | 8.78 | 9.23 | 7.65 | 2368155 | 8.38670575 | CS |
| 26 | 0.5 | 6.21890547264 | 8.04 | 9.28 | 7.61 | 2673026 | 8.25301394 | CS |
| 52 | -2.06 | -19.4339622642 | 10.6 | 10.66 | 6.75 | 2774645 | 8.39267907 | CS |
| 156 | -11.5 | -57.3852295409 | 20.04 | 20.19 | 6.75 | 2936239 | 12.31472051 | CS |
| 260 | -8.19 | -48.9539748954 | 16.73 | 22.67 | 6.75 | 2634724 | 14.56805251 | CS |
Porterhouse10
3 years ago
Porterhouse10
3 years ago
Porterhouse10
3 years ago
Porterhouse10
3 years ago
Porterhouse10
3 years ago
Porterhouse10
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
